Investigational New Drugs

, Volume 24, Issue 3, pp 255–260

Phase II study of interferon-alpha and doxycycline for advanced renal cell carcinoma

Authors

  • Michael Huie
    • University of Wisconsin Comprehensive Cancer Center
  • Kurt Oettel
    • University of Wisconsin Comprehensive Cancer Center
  • Lynn Van Ummersen
    • University of Wisconsin Comprehensive Cancer Center
  • Kyung Mann Kim
    • University of Wisconsin Comprehensive Cancer Center
  • Yulin Zhang
    • University of Wisconsin Comprehensive Cancer Center
  • Mary Jane Staab
    • University of Wisconsin Comprehensive Cancer Center
  • Dottie Horvath
    • University of Wisconsin Comprehensive Cancer Center
  • Rebecca Marnocha
    • University of Wisconsin Comprehensive Cancer Center
  • Jeff Douglas
    • University of Wisconsin Comprehensive Cancer Center
  • Amy Drezen
    • University of Wisconsin Comprehensive Cancer Center
  • Dona Alberti
    • University of Wisconsin Comprehensive Cancer Center
  • George Wilding
    • University of Wisconsin Comprehensive Cancer Center
Phase II Studies

DOI: 10.1007/s10637-005-3903-z

Cite this article as:
Huie, M., Oettel, K., Van Ummersen, L. et al. Invest New Drugs (2006) 24: 255. doi:10.1007/s10637-005-3903-z
  • 48 Views

Summary

Objective: To assess the efficacy and toxicity of the combination of interferon-alpha and doxycycline in patients with metastatic renal cell carcinoma and to assess the effect of this treatment on serum vascular endothelial growth factor (VEGF) levels. Patients and Methods: Seventeen patients with Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1 and life expectancy greater than 4 months with radiologically evident advanced renal cell carcinoma were enrolled. Eight patients had prior nephrectomy and 10 patients were treated within 4 months of their diagnosis. Treatment consisted of interferon-alpha up to 9 million units subcutaneously three times per week and doxycycline 300 mg orally twice per day for weeks one and three of each four-week cycle. Toxicity was evaluated on a biweekly basis and response on a bimonthly basis. VEGF plasma levels were assessed monthly as a measure of potential antiangiogenic effect. Results: No objective responses were seen. The mean duration of study was 2.6 cycles (range: 0.8–6.0 cycles). Three patients (17%) tolerated therapy and displayed stable disease for greater than four months. Five patients withdrew from study before the first response evaluation. Ten patients experienced grade 2 gastrointestinal toxicity requiring dose reduction of doxycycline. Eight patients experienced grade 2 fatigue requiring dose reduction of interferon. VEGF plasma levels were initially suppressed in patients who demonstrated progressive disease but not in patients with stable disease. Conclusion: This regimen of doxycycline and interferon-alpha was not efficacious as treatment for renal cell carcinoma. Plasma VEGF levels were significantly decreased during the first two cycles of treatment, but this does not correlate with clinical outcome.

Key Words

renal cancerinterferonangiogenesisVEGFPhase II trial

Copyright information

© Springer Science + Business Media, LLC 2005